 |
인쇄하기
취소
|
Glaxo's Avandia to face possible ban from Korean market
The Korea Food and Drug Administration is not ban U.K.-based GlaxoSmithKline (GSK)’s blockbuster anti-diabetes pill “Avandia” but stringent restrictions will make it far harder for doctors to prescribe the safety-troubled diabetes drugs.
The European Medicines Agency took harsher action. European sales of Avandia-containing drugs will be suspended over the next few months, although the agenc...
The European Medicines Agency took harsher action. European sales of Avandia-containing drugs will be suspended over the next few months, although the agenc...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.